Table 1: Characteristics of 100 studied patients with HCV genotype 2.

All100
Age57.0(24–76)
Sex (%)
 Male54(54)
 Female46(46)
Height (cm)162(138–186)
Weight (kg)58(37–87)
BMI (kg/m2)22.7(18.4–30.8)
Clinical finding (%)
 Chronic hepatitis93(93)
 Cirrhosis7(7)
WBC (/ L)5100(2100–9730)
Hemoglobin (g/dL)14.0(10–16)
Platelet (104/ L)20.4(6.9–26.5)
AST (IU/L)42(17–157)
ALT (IU/L)52(11–280)
TC (mg/dL)177(106–269)
177 mg/dL (%)50(50)
177 mg/dL (%)50(50)
TG (mg/dL)88(56–262)
88 mg/dL (%)50(50)
88mg/dL (%)50(50)
LDL-C (mg/dL)98(30–167)
98 mg/dL (%)50(50)
98 mg/dL (%)50(50)
HCV RNA (KIU/mL)1000(20–40900)
Distribution of stage of fibrosis (%)
 0-143(43)
 217(17)
 311(11)
 44(4)
 Unknown25(25)
Distribution of grade of inflammation (%)
 0-139(39)
 234(34)
 32(2)
 Unknown25(25)
Treatment period (week) (%)
2410(10)
 2483(83)
 25–485(5)
482(2)
Therapeutic efficacy (%)
 SVR74(74)
 Non-SVR26(26)

Data are median (range) or frequency (%).